Medical University of South Carolina

MEDICA
MUSC Theses and Dissertations
2011

Regulation of Membrane-Type 1 Matrix Metalloproteinase
Abundance by Selective Modulation of MicroRNA-133a
Adam William Akerman
Medical University of South Carolina

Follow this and additional works at: https://medica-musc.researchcommons.org/theses

Recommended Citation
Akerman, Adam William, "Regulation of Membrane-Type 1 Matrix Metalloproteinase Abundance by
Selective Modulation of MicroRNA-133a" (2011). MUSC Theses and Dissertations. 14.
https://medica-musc.researchcommons.org/theses/14

This Thesis is brought to you for free and open access by MEDICA. It has been accepted for inclusion in MUSC
Theses and Dissertations by an authorized administrator of MEDICA. For more information, please contact
medica@musc.edu.

Regulation of Membrane-Type 1 Matrix
Metalloproteinase Abundance by Selective
Modulation of MicroRNA-133a
By
Adam William Akerman

A thesis submitted to the faculty of the Medical University of South
Carolina in partial fulfillment of the requirements for the degree of Masters
in Biomedical Science in the College of Graduate Studies.

Department of Microbiology and Immunology

2011
Approved by:
Chairman,AdvisoryCommittee~~~~~~~~~~~~~~~

Laura Kasman, Ph.D.

-----..-.

Michael R. Zile, M.D.

TABLE OF CONTENTS

ABSTRACT ........................................................................................... i
CHAPTERS
1. INTRODUCTION ........................................

1, •••••••••••••••••••••••••••

1

Hypothesis .........................................................................3
Specific Aims ......................................................................4
2. REVIEW OF LITERATURE ........................................................5
Clinical Significance ..............................................................5
Pathophysiology of DCM: Changes in Extracellular Matrix ... 8
Summary ......................................
Innovation .....................

I

I

••••••••••••••••••••••••••

••••••••••••••••••••••••••••••••••••••••••••••••••••

Summary ....................................

I

•••

II

I

••••••••••••••••••••••

15
17
19

3. PRELIMINARY STUDIES ......... , ...............................................21
Summary: Preliminary Studies ..............................................30
4. RESULTS AND DiSCUSSiON ...................................................31
Experimental Design ...........................................................31
Specific Aim 1 ..........................................................36
Approach ........................................................36
Specific Methods ............. ,

I

•••••

I

••••

I

•••••••••••

I

•••••••

36

Response variables .......................................... 37

Data Analysis ..................................................37
Specific Aim 2 ..........................................................37
Approach ........................................................37
Specific Methods and Results ............................. 38
Data Analysis ..................................................47
Specific Aim 3 ..........................................................48
Approach ........................................................48
Specific Methods ............................................. 48
Results ..........................................................49
Data Analysis ................................................. 51

5. FUTURE DIRECTIONS ............................................................ 52

6. SUMMARy ............................................................................62

REFERENCES ....................................................................................62

ADAM W. AKERMAN. Regulation of Membrane-Type 1
Matrix Metalloproteinase Abundance by Selective
Modulation of MicroRNA-133a. (Under the direction of
JEFFREY A. JONES)
ABSTRACT
BACKGROUND: A significant increase in the myocardial abundance of
Membrane-Type 1 Matrix Metalioproteinase (MT1-MMP) has been identified in
patients suffering Dilated Cardiomyopathy (OeM). These increased levels likely
contribute to OeM; however, the molecular basis for up-regulation of MT1-MMP
in the context of OeM remains unknown. Of significant relevance, microRNAs
fine-tune protein translation by interrupting ribonucleoprotein:mRNA complexes,
inducing degradation, or more commonly, translational repression of the
message.

Therefore, the aim of this study was to identify an endogenous

microRNA responsible for the specific alterations correlating with disease state,
and demonstrate a method of translational regulation of MT1-MMP.

METHODS AND RESULTS:

To identify potential regulatory microRNAs, a

bioinformatics approach was taken to examine the MT1-MMP transcript for
putative interaction sites.
investigation.

As a result, miR-133a was selected for further

Using a commercially available reporter vector, constructed by

cloning the 3' untranslated region (UTR) of the human MT1-MMP transcript
downstream of a luciferase open reading frame, miR-133a was confirmed to
directly target MT1-MMP's 3'UTR and selectively reduce translation with a
significantly high level of efficiency in HT1080 cells. Investigations continued in a

myocardial fibroblast model of OCM, developed and validated by this laboratory,
and through reverse-transcription quantitative PCR (RT-qPCR), have, most
interestingly, identified miR-133a microRNA levels to be significantly reduced in
OCM myocardial fibroblasts (n=5) when compared to normal (n=4).

Utilizing

tools for permanent over expression and inhibition of miR-133a, the present
study has successfully demonstrated, by protein immunoblot, a significant
reduction in MT1-MMP protein abundance with miR-133a over expression, as
well as, a significant increase in MT1-MMP protein abundance with miR-133a
knockdown, in both normal and DeM myocardial fibroblasts.

These findings

were not accompanied by any significant change in MT1-MMP mRNA levels, and
did not elicit induction of an interferon response, determined by RT-qPCR.

CONCLUSIONS:
expression

in

The present study identifies aberrant miR-133a microRNA

OeM,

confirms MT1-MMP as a target of miR-133a and

demonstrates a method of translational regulation of MT1-MMP by direct
modulation of miR-133a in normal and OeM myocardial fibroblasts.

These

findings hold diagnostic and therapeutic relevance for one of the most urgent
public health problems in the United States.
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CHAPTER 1: INTRODUCTION

A structural event in the progression of heart failure is myocardial
extracellular matrix (ECM) remodeling. ECM remodeling is an important process
in regulating the dynamic balance between degradation and deposition in which
a critical family of proteolytic enzymes, the matrix metalloproteinases (MMPs),
actively participate. Recent advances in the understanding of cardiovascular
disease processes have identified specific changes in the abundance and activity
of a common membrane bound form, Membrane-Type 1 MMP (MT1-MMP),
which functions in the modification of matrix structural proteins, activation of other
MMPs, and proteolytic processing of bioactive molecules including: growth
factors, cytokines/chemokines and interleukins30 •
The most numerous cell type in the heart is the cardiac fibroblast. In several
cardiovascular diseases (heart failure, thoracic aortic aneurysm, and myocardial
infarction) these endogenous fibroblasts undergo a cellular phenotype change
that is accompanied by an increase in MT1-MMP abundance and enhanced
ECM remodeling 8 ,21,46. Elucidation of these diverse functions has also revealed
that MT1-MMP can act on pro-inflammatory cytokines/chemokines and other
proteins to regulate various aspects of the inflammatory response 2S ,33. Together,
these studies suggest that MT1-MMP may be a turnkey mediator of ECM

1

remodeling in cardiovascular disease, and suggest that strategies targeting this
protease may have significant clinical implications.
Recently, microRNAs, a class of small, non-coding RNA, function to fine tune
protein translation by interaction with the 3'-untranslated region (UTR) of targeted
mRNAs, have been identified as endogenous upstream regulators of MMPs and
have been promoted as potential therapeutics for heart disease 6,21,4o. Aberrant
microRNA expression is a recognized pathogenic means of disease, and is
emerging as a clear mechanism mediating changes in ECM remodeling
pathways; however, whether and to what degree microRNAs regulate the
translation

of

MT1-MMP

remains

uncharacterized.

Incidentally,

through

bioinformatic examination of MT1-MMP transcript, a putative miR-133a binding
site was identified within the 3'-UTR. Therefore, by utilizing a cellular model of
primary myocardial fibroblasts isolated from left ventricular biopsies of normal
(n=4) and dilated cardiomyopathy (DCM) patients (n=5), this study has identified
that endogenous miR-133a levels influence critical steps in extracellular matrix
remodeling and cellular phenotype through the modulation of MT1-MMP protein
abundance.

')

Hypothesis
Endogenous miR-133a levels influence critical steps in extracellular matrix
remodeling and cellular phenotype through the modulation of MT1-MMP protein
abundance in normal and DeM LV myocardial fibroblasts (Figure 1-1).
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Figure 1-1 . Hypothesis: miR-133a levels influence critical steps in ECM remodeling and
cellular phenotype throuqh the modulation of MT1-MM P protein abundance.
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Specific Aims
1) Demonstrate DCM fibroblasts have a unique phenotype compared to
normal

fibroblasts.

demonstrate

Utilizing

differential

primary

steady-state

myocardial

MT1-MMP

fibroblast

expression,

cultures:
ribosomal

distribution (translational efficiency), protein abundance, and activity.

2) Establish miR-133a as a post-transcriptional regulator of MT1-MMP. a)
Demonstrate that Normal and DCM myocardial fibroblasts can be transfected
by viral vectors to over express miR-133a or anti-miR-133a. b) Following
transduction, determine the presence of an activated non-specific cellular
stress response elements. c) Establish the mechanism by which miR-133a
regulates MT1-MMP protein abundance by quantifying MT1-MMP transcript
levels and ribosomal distribution.

3) Determine the effect of miR-133a modulation on phenotypic differences
between normal and DCM fibroblasts. Through the viral-mediated over
expression of miR-133a or anti-miR-133a demonstrate that: a) in normal
fibroblasts,

the knockdown

of miR-133a enhances MT1-MMP protein

abundance and activity, inducing the phenotypic differences as defined in
specific aim 1; while b) in DCM fibroblasts over expression of miR-133a
suppresses MT1-MMP protein abundance and activity, and returns the cells to
a "normal phenotype" as defined in specific aim 1.
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CHAPTER 2: REVIEW OF LITERATURE
Clinical Significance
Cardiovascular disease (CVD) represents a leading cause of morbidity and
mortality, emphasizing the need for innovative therapies and diagnostics 37 . One
in three American adults has some form of CVD21. Heart disease and stroke are
the most common forms, and are leading causes of death for both men and
women in the United States37 (Figure 2-1); however, current indicators suggest
460,000
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Figure 2-1. Cardiovascular disease and other major causes of death for all males and
females. A, cardiovascular disease plus congenital cardiovascular disease; B, cancer; C,
accidents; 0, chronic lower respiratory disease; E, diabetes mellitus; F, Alzheimer disease.
Source: National Center for Health Statistics and National Heart, Lunq, and Blood Institute.
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there has been a relative shift away from drug development for heart failure by
the pharmaceutical industry. This is believed to be result of multiple failures late
in the clinical trial process for a number of pharmacological agents, including
those for TNF blockers3 and even most of the MMP inhibitors22 . CVD is defined
as an abnormal function of the heart and/or blood vessels. The causes of CVD
range from structural defects to infection, inflammation as well as environmental
and genetic factors. CVD can cause an increase in risk for heart attack, heart
failure, sudden death, stroke, cardiac rhythm problems, and aortic aneurysms,
thus resulting in diminished quality of life and decreased life expectancy.
Heart failure (HF) is the pathophysiologic state diagnosed using a confluence
of symptomology, in which the heart fails to pump blood at a rate commensurate
with the requirements of the metabolizing tissues. One such example of disease
is dilated cardiomyopathy (DeM) (Figure 2-2), and is characterized by dilation of
the left ventricle (LV) and impaired pump contraction of the affected ventricle
resulting in progressive heart failure 11. The compliance of the LV myocardium is
determined by the physical properties of the cardiac muscle and other tissues
making up the ventricular wall. Alterations in cardiovascular stress initiate a
multifaceted response in the LV to attempt normalization of the imposed strain?
This response can include alteration in cellular shape and changes in the amount
and type of collagen as well as degree of collagen cross-linking 42 . Frequently
these changes are associated with decreased ventricular compliance, which
results in the progressive reduction of normal cardiac pump function.
continued elevation in wall stress exceeds the ability of the heart to compensate,
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Figure 2-2. Illustration of normal and OeM. A OCM heart illustrating characteristic dilation of
the left ventricle, and disproportionately reduced ventricular wall thickness (Right). A normal
heart is illustrated on the left for comparison. Gross anatomical and pathological illustrations by
Cathryn T. Akerman.

then the ventricular wall thickness is disproportionately reduced compared to
chamber volume and diastolic and systolic dysfunction ensues43 .
The overwhelming majority of patients diagnosed are described as having
acquired an idiopathic DCM, a disease of unknown cause 21 . Specific treatments
are not available for most patients with idiopathic DCM 11 . Therefore, the primary
aims of the limited current therapeutic goals are to relieve/stabilize associated
symptoms and prolong survival by halting or reversing the progression of
myocardial dysfunction 20 . To gauge the current extent and focus of federally and
privately supported clinical trials in heart failure, conducted within the United
7

States and around the world, the NIH Clinical Trials Registry was examined.
This database identified 74 ongoing clinical trials in 2011, with a principal focus
on heart failure.

Of these trials, 23%

were device based and 15%

were

procedure based trials, with primary focuses on addressing modifications of
existing biventricular pacing and automatic implantable defibrillator technology,
telemonitoring devices, or evaluating the utility of new devices for the delivery of
cell therapy24.

Interestingly, only 8%

of the studies are based on the actual

delivery of biological based therapeutics. The remaining 54% of trials evaluating
pharmacotherapy for heart failure are directed toward evaluation of treatment
efficacy. Treatment of heart failure targets early steps in signaling pathways,
such as cell surface receptors, calcium channels, handling proteins, and
components of the ~-adrenic receptor system 51 ; however, given the multitude of
signals contributing to the progression of myocardial dysfunction, single target
therapy has proven to be insufficient. Therefore, an alternative approach that
targets multiple pathways within complex disease phenotypes may be more
efficacious.

Pathophysiology of OeM: changes in extracellular matrix

The changes in myocardial structure and function leading to the progression
of OCM result from the combined actions of cellular and extracellular factors
which govern the constitution of the extracellular matrix (ECM) and playa critical
role in the homeostatic remodeling process. Collagens, the chief components of
the ECM, are a tightly regulated family of proteins that determine the structural
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and functional integrity of the heart.

The dynamic balance between ECM

degradation and deposition is mediated by a family of proteolytic enzymes
capable of degrading all ECM components, the matrix metalloproteinases
(MMPs). Several MMP types have been identified within the human myocardium
to be pathologically dysregulated in OCM44.

For example, MMPs that are

expressed at very low levels in normal myocardium, such as, gelatinase A
(MMP2) and membrane-type 1 (MT1) MMP (MT1-MMP), are substantially up
regulated. The MMPs are produced by both the endogenous cells within the
myocardium (myocytes, fibroblasts), as well as the infiltrating inflammatory cells
(macrophages, neutrophils, 8-cells, T-cells).
Past studies involving histological and biochemical analyses of OCM have
provided the foundation and rationale for identifying a direct relationship between
myocardial remodeling and matrix metalloproteinase (MMP) induction and
activation within the myocardium of patients suffering from heart failure 43 ,44,45. In
particular, the available experimental data indicate the trans-membrane topology
of MT1-MMP may allow this enzyme the unique ability to profoundly influence the
ECM through direct involvement with remodeling and, in parallel, actively
participate in the signaling events involved in the cell response to these
modifications 14.

Of all the MT-MMPs, MT1-MMP is the best characterized. MT1-MMP is a
fully active enzyme once inserted into the cell membrane and contains an
extracellular catalytic domain, hinge region, hemopexin-like repeat domain, stem,
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a transmembrane domain, and an intracellular cytosolic tail, all of which are
critical for full functioning of the protease (Figure 2-3).
EXTRACELLULAR
MATRIX
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Figure 2-3. Domain structure and location of active MT1-MMP.
domain; TM, trans-membrane domain; CT, cytosolic tail.

H, hemopexin-like

Membrane Type 1-MMP has been shown to play a critical role in the
pericellular degradation of connective tissue matrix by directly hydrolysing native
collagen I, and indirectly by initiating a cascade of zymogen activation at the cell
surface, which leads to the generation of active MMP2.

MT1-MMP also

degrades a variety of surface associated proteins, including growth factors,
cytokines and cell adhesion receptors, further indicating its function as a major
mediator of surface proteolysis.
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A control point for MMP activity is through the inhibition of the activated
enzyme by the action of a group of specific MMP inhibitors known as the Tissue
Inhibitors of Metalloproteinase (TIMPs), of which there are four known species.
TIMPs bind to the catalytic domain of active MMPs, preventing access to
substrates. Figure 2-4 demonstrates the complex formed by the MT1-MMP with
TIMP-2.

Figure 2-4 . Space fill view of the MT1-MMP:TIMP-2 complex. MT1-MMP catalytic domain
(PURPLE), TIMP-2 (BLUE). Figures drawn with MMDB (Madej, 2012).
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Previous studies performed by this laboratory have identified that myocardial
MT1-MMP protein abundance is elevated in the left ventricle of patients with
DCM 44 (Figure 2-5). These increased tissue levels of MT1 -MMP protein likely
Myocardial MTI-MMP Protein Abundance
MTl -MMP
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Figure 2-5. MT1-MMP protein abundance is elevated in the left ventricular myocardium of
OCM (n=21) patients compared to normal (n=13). Source: Circulation 102; 2000.

contribute to changes in matrix structure and function in the DCM myocardium.
These past investigations, while of great significance, were limited to the ability of
only providing insight into the cellular and molecular basis for altered myocardial
MMP activity occurring in end-stage human heart failure, and moreover,
demonstrate the importance of new large animal models and translational studies
designed to target the underlying mechanisms which contribute to the
progression of disease.
The myocardial fibroblast

IS

the most numerous cell type within the

myocardium and functions as a key mediator of pericellular proteolysis critical in
degradation of the ECM 15 . Therefore a potential therapeutic cell target would be
to regulate myocardial fibroblast form and function . The directions of this study
12

include mechanisms' of cardiovascular remodeling with an emphasis on
translational regulatory pathways that control unique enzymes in the extracellular
space and contribute to changes in cellular phenotype and how this proteolytic
pathway, known to promote cardiovascular disease, may be regulated.
In human heart failure, such as DeM, increased and prolonged neurohormonal activity and the release of biologically active molecules occurs, which
culminates in the formation of a number of up-stream transcription factors, and in
turn may induce prolonged changes in MMP and other pro-fibrotic gene
transcription 43 • The MT1-MMP promoter region is unique from other MMP types
in that it contains a number of distinct response elements. For example, three
transforming growth factor (TGF) inhibitory elements (TIEs) which bind the family
of Smad transcription factors, and one GC box which binds SP1 transcription
factors, have been identified 45 (Figure 2-6).
-753

-664

ICCAATI I CCAAT I

-597 -552 -540

®@®

-370

-148

ICCAATI ICCAATI

-92

A

rMTI-MMP

Figure 2-6. MT1-MMP promoter region.
CCAAT (or ATTGG), CCAAT box; TIE,
Transforming growth factor inhibitory element; GC, SP1 binding site.

Following transcription and subsequent nuclear export, a number of posttranscriptional steps are required for insertion of MT1-MMP into the cell
membrane as well as release of soluble MMP2. The activation of the soluble
MMP2 requires proteolytic cleavage of the prodomain, which occurs primarily by
MT1-MMP. This activation step provides for focal proteolytic activity, but can
quickly amplify as additional MT1-MMP or soluble MMP2 is synthesized 43 •

13

In addition to MT1-MMP's ability to directly activate pro-inflammatory
cytokines33 , it has also been demonstrated that interaction with the Latent
Transforming Binding Protein-1 (LTBP-1) resulting in the release of active
Transforming Growth Factor

~ (TGF-~).

The TGF-

~

superfamily plays a critical

role in the regulation of cell growth, differentiation and development in normal
and pathological development.

Signaling is initiated with ligand-induced

oligomerization of serine/threonine receptor kinases and phosphorylation of the
cytoplasmic signaling molecules Smad2 and

Smad3.

Carboxy-terminal

phosphorylation of Smads by activated receptors results in their partnering with
the common signaling transducer Smad4, and translocation to the nucleus.
Activated

Smads

regulate

diverse biological

effects by partnering with

transcription factors resulting in cell-state specific modulation of transcription.
Activation of Smad-independent pathways through

TGF-~

signaling is also

common. Rho GTPase (RhoA) activates downstream target proteins, such as
mDia and ROCK, to prompt rearrangement of the cytoskeletal elements
associated with cell spreading, cell growth regulation, and cytokinesis46 . Figure

2-7 illustrates MT1-MMP's key role in this pathological process leading to DCM
disease state.

14

EXTRPCELLULAR
MATRIX
Hydrolysis

'\:-00 '"
'·'_·~I I it¢.~ci_;:...:::~~/

_____

ACTIVE

...

V

L

~
t

_-_. ,.... .

.....

,..~-'

/ '"

'"

_....

---- -- -

.
•
...
-- -:..--

Polymerizatio n
- - "' - -- . . . Stress Fibers

--------

,-

..

......... . .

'"

/

I

I

/

....

,
/

I
I

...•

'~"'"

~/"

NJCLEUS

,

.... ....
\

~

....

\

\

~\

,l

~

~

•

CARDIAC

REMODELING

j

Figure 2-7. MT1-MMP's key role in the development of Dilated Cardiomyopathy. The
changes in myocardial structure and function leading to the progression of OCM result from
the combined actions of cellular and extracellular factors which govern the constitution of the
extracellular matrix (ECM) and playa critical role in the homeostatic remodeling process.

Summary: Clinical Significance

A significant increase in the myocardial abundance of MT1-MMP has been
identified in OeM patients, and these increased levels likely contribute to OeM;
however, the molecular basis for the up-regulation of MT1-MMP in the context of
oeM remains unknown.

Since OeM is a progressive myocardial disease

process that culminates in severe heart failure and hemodynamic collapse,
mechanical assist devices and/or heart transplantation are often required.

As

such, access to myocardial samples from OeM patients is possible and has
15

allowed for an extensive survey of MT1-MMP. The myocardial fibroblast is the
most numerous cell type within the myocardium and functions as a key mediator
of pericellular proteolysis critical in degradation of the ECM.

Therefore a

potential therapeutic cell target would be to regulate myocardial fibroblast
phenotype through modulation of MT1-MMP protein abundance.

16

INNOVATION
This novel study characterizes a method of post-transcriptional regulation of
MT1-MMP protein abundance by direct modulation of a particular microRNA,
miR-133a, known to be enriched in cardiac and skeletal muscle, and involved in
cell specification, differentiation, and development5 ,1o. MicroRNAs have recently
been identified as new putative therapeutics for heart disease 6 , and are also
known endogenous upstream regulators of MMP S 6,21,34. MicroRNAs, a class of
naturally-occurring, small non-coding RNAs, are highly conserved among
species, and fine-tune protein translation by interrupting ribonucleoprotein:mRNA
complexes, inducing degradation, or more commonly, translational repression of
the message34 •

Of significant relevance, aberrant microRNA expression is a

recognized pathogenic mechanism of disease, and is beginning to be identified
as key in regulation of specific proteins involved in extra cellular matrix
remodeling pathways.
MicroRNA biogenesis is outlined

In Figure 2-8,

endogenous mechanism of translational regulation.
mediated biological regulation is vast.

and

illustrates an

The impact of microRNA

It is estimated that microRNAs post-

transcriptionally regulate over 60% of all protein coding genes23 • An especially
powerful feature of microRNA mediated regulation is the ability of a single
microRNA to regulate multiple functionally related mRNAs.

The targeting of

multiple mRNAs that participate in common cellular processes contrasts with the
approach of most drug therapies, which are directed at highly specific targets,
and enables microRNAs to effectively regulate complex intracellular pathways,

17

thereby potentially avoiding redundant mechanisms that may bypass a single
inhibited target.

Figure 2-8. microRNA Biogenesis and Mechanism of Gene Regulation. Like all classes of
RNA, microRNAs are transcribed from DNA. Like mRNAs, this nuclear process is RNA
polymerase II dependent and regulated by transcription factors (1.). If the gene transcribed
encodes a protein, the result is messenger RNA (mRNA), which will then be used to create that
protein in the process of translation. Alternatively, particular non-gene coding regions as well as
non-protein coding portions of DNA transcriptional units, such as introns, may be transcribed to
produce translational regulatory sequences. Transcription generates a long primary transcript,
termed the primary microRNA (2.). Following transcription, microRNA processing continues with
hydrolysis of the transcript by the enzyme Drosha to produce a precursor microRNA (3.), which
then interacts with Exportin-5 (XPO-5) (4.) and is then exported from the nucleus to the cytoplasm
(5.) where further hydrolysis by the Dicer Ribonuclease removes the loop portion of the precursor
microRNA (6.), generating a double stranded microRNA duplex (7.). In the cytoplasm , final
processing occurs as the microRNA duplex interacts with Argonaut (AGO) protein (8.) and is
stripped of its complementary passenger strand (9.). Incorporation of accessory protein, GW182,
forms the RNA-Induced Silencing Complex (RISC), which can interact with the 3'UTR of target
mRNAs (10.) resulting in two possible outcomes. Dependent upon the level of homology
between the microRNA and targeted mRNA sequences: if the homology is high, the targeted
mRNA transcript is degraded (11.); or if the homology is low, imperfect base paring between the
microRNA and mRNA results in translational repression (12.). The latter outcome occurs in 85%
of interactions. In this scenario the RISC Complex functions by using the incorporated mature
microRNA sequence as a target recognition component. This allows for imperfect interaction with
complementary binding sites predominantly located in the 3' UTR of a targeted mRNA and results
in translational repression of that particular message.

18

MicroRNAs interfere with translation by interaction with the 3'UTR.

It is

believed that the RiSe complex inhibits translation initiation by interfering with
elF4F-cap recognition and 40S small ribosomal subunit recruitment or by
antagonizing 60S subunit joining and preventing 80S ribosomal complex
formation. Ding et al. reported that an interaction of the GW 182 protein with the
poly(A)-binding protein (PABP) might interfere with the closed-loop formation of
the mRNA, mediated by the eIF4G-PABP interaction, and thus contribute to the
repression of translation initiation 10.

Summary: Innovation

An especially powerful feature of microRNA based regulation is the ability of
single microRNAs to regulate multiple functionally related mRNAs6.

The

targeting of multiple mRNAs that participate in common cellular processes
contrasts with the approach of most drug therapies, which are directed at highly
specific targets, and enables microRNAs to effectively regulate complex
intracellular pathways, thereby potentially avoiding redundant mechanisms that
may bypass a single inhibited target.

This however raises concern over the

possibility that the targeted modulation of a particular microRNA may, at the
same time, interfere with beneficial cellular functions 6 .

While a great deal

remains to be understood, the concept of microRNA manipulation to regulate
complex disease related processes is becoming a feasible future therapeutic
approach 6 .

Moreover, identification of an endogenous microRNA that may

influence critical steps in extracellular matrix remodeling pathways of myocardial

19

fibroblasts through modulation of MT1-MMP protein abundance, and subsequent
elucidation of the cellular and molecular pathways responsible for the specific
alterations correlating with heart failure holds diagnostic and therapeutic
relevance for one of the most urgent public health problems in the United States.

20

CHAPTER 3: PRELIMINARY STUDIES
Previously, this laboratory has determined that MT1-MMP protein levels are
increased in the tissue associated with several cardiovascular diseases, and
these specific differences were replicated in fibroblast cultures43 . Flack et. al.
demonstrated that the myocardial fibroblasts isolated from a large animal model
of pacing induced LV failure exhibited quantifiable phenotypic

alterations

persistent throughout sub-cultivation in the absence of external biological or
physical stimuli when compared to normal 13 . Therefore, investigations continued
in a myocardial fibroblast model of OCM, developed and validated by this
laboratory. Accordingly, LV biopsies from non-failing, reference normal patients
possessing a >50% LV ejection fraction, undergoing elective coronary bypass
surgery and possessing no perfusion defects at site of biopsy (n=4), and endstage DeM patients with an LV ejection fraction of <20% at time of transplant
(n=5), were extracted and used to establish primary fibroblast cultures.

The

biopsies were extracted from the same region of the LV, and were processed for
culture in an identical fashion. Cell cultures were confirmed to be pure fibroblasts
by immunochemistry using antisera against a panel of antibodies and were
positive for actin, which is selectively bound by phalloidin 51 ; the discoidin domain
receptor 2 (DDR2), DDR2 protein expression is confined to fibroblasts, and is not
expressed on myocytes, endothelial or smooth muscle cells 16; and prolyl-4-
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hydroxylase, an enzyme involved in the synthesis of collagens; but were negative
for smooth muscle myosin heavy chain (Figure 3-1). In addition, immunoblotting

Phalloidin

Prolyl-4hydroxylase

DDR2

Myosin

Figure 3-1. Cell cultures were confirmed to be pure fibroblasts by immunochemistry using
antisera against a panel of antibodies and were positive for actin (phalloidin), the discoidin
domain receptor 2 (DDR2) and prolyl-4-hydroxylase but were negative for smooth muscle
myosin heavy chain. DAPI was used as a nuclear counterstain (blue).

for this panel of antisera was performed routinely on cell passages to ensure
phenotypic stability with respect to these fibroblast markers. The isolated
myocardial fibroblasts were maintained in complete fibroblast specific growth
media (PromoCell) with added 10% Fetal Bovine Serum (Gibco), antimycotic
Amphotericin B (5 ug/mL) and the aminoglycoside antibiotic, Gentamicin (0.5
mg/mL) at 37°C in 5% CO 2 . Utilizing this approach, confluent LV fibroblasts from
culture passages 2-8 were measured with respect to MT1-MMP protein
abundance and activity, as well as MT1-MMP mRNA levels and ribosomal
distribution.
For this purpose, myocardial fibroblast cultures were grown to confluence in
sterile T-75 Falcon culture flasks with complete fibroblast growth media then
washed once with D-PBS, with calcium and magnesium, and then serum starved
in FBS reduced fibroblast growth media overnight.
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Growth Media was then

aspirated and cells were collected uSing a PBS-based, enzyme-free, celldisassociation buffer. Collection of cells by this method preserves the structural
and functional integrity of cell surface proteins 18.

Whole cell pellets were

collected under steady state conditions, and MT1-MMP abundance was
assessed by immunoblotting in the following fashion.
protein

(1 Dug),

extracted

from

the

cell

pellet,

Equal amounts of total

were

loaded

onto

polyacrylamide gels and transferred onto nitrocellulose membranes.
blocking for 1 hour in 5%

10 %
After

milk at room temperature, the membranes were

incubated for 1 hour at 37°C In primary anti-sera for Human MT1-MMP
hemopexin domain (AB8221). As shown in Figure 3-2, MT1-MMP protein levels
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Figure 3-2. MT1-MMP Protein Abundance. MT1-MMP protein abundance is significantly
elevated in LV myocardial fibroblasts isolated from OeM patients when compared to normal.
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were found to be significantly elevated in sub-cultivated OCM myocardial
fibroblasts as compared to normal. To verify that the observed increase in MT1MMP protein abundance correlated with proteolytic activity in OCM, the amount
of active MT1-MMP was quantified in whole cell homogenates using a specific
fluorescent resonance energy transfer peptide substrate, where in the intact
peptide, fluorescence is quenched. Upon hydrolysis of the peptide sequence by
MT1-MMP, the quenching group separates from the fluorophore allowing
fluorescence to be quantitated. Results from this assay demonstrate that MT1MMP specific activity over a 15 hour period of time, was indeed increased In
oeM myocardial fibroblasts when compared to normal (Figure 3-3).
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Figure 3-3. MT1-MMP Activity. MT1-MMP activity is significantly elevated in LV myocardial
fibroblasts isolated from OeM patients when compared to normal. Data are represented as
mean (solid line) +/- standard error of the mean (shaded regions).
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Little is known about the transcriptional and translational regulatory
mechanisms controlling MT1-MMP protein abundance in human myocardial
fibroblasts.

In consequence, MT1-MMP mRNA levels were assessed by

quantitative RT-PCR during steady state conditions.

Cells were grown to

confluence in sterile 60mm Falcon culture dishes with complete fibroblast growth
media then washed once with D-PBS and serum starved in FBS reduced
fibroblast growth media for 24 hours. Growth Media was then aspirated and cells
were lysed directly in

RLT plus lysis buffer (Qiagen) with added 2-

Mercaptoethanol (10/0) to eliminate ribonucleases released during cell lysis. Total
RNA was then isolated and purified using the Qiagen RNeasy Plus kit with
Genomic DNA (gONA) eliminator spin column, and determination of total RNA
purity and concentration was performed using The Experion RNA StdSens
analysis kit (Caliper Life Sciences, Inc. Bio-Rad Laboratories). Total RNA was
reverse transcribed with the modified MMLV-derived reverse transcriptase and
blend of oligo(dT} and random hexamer primers contained in the iScript cDNA
Synthesis Kit (BioRad). Single-stranded cDNA was synthesized from 1 ug total
RNA in 20 uL reaction volume with iScript eDNA SyntheSiS Kit (BioRad),
according to the manufacturer's protocol. The reaction was incubated at 25°C for
5 min followed by 30 min at 42°C and inactivation at 85°C for 5 min. Each cDNA
was amplified with sequence-specific TaqMan Gene Expression Assays from
Applied Biosystems. PCR reactions were performed on a Bio-Rad CFX96 RealTime System in 25 uL volumes in a 96-well plate at 95°C for 10 min, followed by
40 cycles of 95°C for 15 sec and 60°C for 1 min. All samples were tested in
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duplicate. The relative expression of each mRNA was calculated and normalized
to the internal control 18S rRNA using the comparative cycle threshold (CT)
method (Livak and Schmittgen, 2001). Relative expression intensity values were
calculated as 2-~CT, in which ~CT are CT values normalized to the reference
control.

Consistent with elevated MT1-MMP protein abundance and activity,

MT1-MMP mRNA levels were observed to be significantly elevated in OCM
myocardial fibroblasts compared to normal (Figure 3-4).

MT1-MMP mRNA Levels
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Figure 3-4. MT1-MMP mRNA Levels. MT1-MMP mRNA is significantly elevated in LV
myocardial fibroblasts isolated from OeM patients when compared to normal.

To determine if increased MT1-MMP abundance in OCM fibroblasts may be
due to alterations in translational efficiency, ribosomal fractionation studies were
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performed.

The fibroblasts were grown to confluence in sterile T-150 Falcon

culture flasks with complete fibroblast growth media then washed twice with 4°C
PBS, without calcium or magnesium, containing cycloheximide (10ug/ml). The
fibroblasts were then collected by scraping, and dounce-homogenized in a 4°C
buffer containing 10 mM Tris, pH 7.5, 250 mM KCl, 10 mM MgCb, 0.5% Triton
X-100, 2 mM DL-Dithiothreitol (DTT) , 100 ug/ml cycloheximide, and 2 ul
RNAsin (Promega).

Tween-deoxycholate (20%) was added to the cell

homogenate, then incubated for 15 min at room temperature, and then
centrifuged at 4°C for 15 min at 13,000 g to produce a post-mitochondrial
supernatant, which was then layered onto a 15-500/0 sucrose gradient containing
20 mM Tris, pH 7.5, 250 mM KCl, 10 mM MgCI 2 , and 80 units of RNAsin. The
samples were then subjected to ultracentrifugation at 100,000 g for 100 min at
4°C, and gradients were fractionated on an

Isca

yielding ten fractions of equal volumes (1 mL).

density gradient fractionator,
The first five fractions of the

gradient separation contain monosomes that include free 40S and 60S ribosome
subunits, and mRNAs assembled into messenger ribonucleoprotein (mRNp)43.
The next 5 fractions contain polysomes, which consist of mRNAs that are active
in translation. The RNA was then extracted and purified from each fraction and
MT1-MMP and glyceraldehydes-3-phosphate dehydrogenase (GAPDH), one of
the most commonly used housekeeping genes in comparisons of gene
expression data, mRNA levels were determined by RT-PCR as described in the
preceding section. Total translational capacity and ribosomal abundance was
taken into account by normalizing the individual mRNAs of interest (MT1-MMP
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and GAPDH) to the 188 ribosomal RNA (rRNA) subunit. The entire distribution
of MT1-MMP and GAPOH mRNAs across both monosomal and polysomal
fractions were examined.

For this approach, the first half of the gradient

(fractions 1-5) were considered monosomal and the second half (fractions 6-10)
were considered polysomal. This categorical approach accounts for small shifts
in the resolution of adjacent polysome fractions, following sucrose gradient
centrifugation, within each experiment. Relative expression intensity values were
calculated as 2-~CT, in which ~CT are CT values normalized to the reference
control, and the data is presented as a percent of total mRNA distributed. These
preliminary observations demonstrate MT1-MMP mRNA in normal myocardial
fibroblasts is largely within monosomal fractions; however, in OeM myocardial
fibroblasts, MT1-MMP mRNA is predominantly within polyribosomal fractions
(Figure 3-5). These observations suggest an increase in MT1-MMP translational
efficiency in DeM myocardial fibroblasts.

To demonstrate that increased

translational efficiency is not a global characteristic of OCM, GAPOH mRNA
across both monosomal and polysomal fractions was examined in an identical
fashion.

In both normal and OCM myocardial fibroblasts, GAPOH mRNA is

predominantly within monoribosomal fractions (Figure 3-6).

Combined, these

findings suggest that specifically MT1-MMP translational efficiency is highly
elevated in OeM myocardial fibroblasts when compared to normal.
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Figure 3-5. MT1-MMP Ribosomal Distribution. MT1-MMP mRNA in normal myocardial
fibroblasts is largely within monosomal fractions. In OCM myocardial fibroblasts, MT1-MMP
mRNA is predominantly within polyribosomal fractions.
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Summary: Preliminary Studies
As myocardial fibroblasts, harvested and expanded in culture from patients
with end-stage OCM, exhibit persistent alterations in signaling, transcriptional
and post-translational pathways requisite for MT1-MMP processing 26 , the present
study will move beyond in vivo observational investigations of MT1-MMP and
demonstrate modulation of the molecular signals and pathways that cause
persistent abnormalities in matrix degradation pathways in a human myocardial
cellular model of OCM. This will allow for the resolution of the described aims
and hypothesis that miR-133a levels influence critical steps in ECM remodeling
and cellular phenotype through the modulation of MT1-MMP protein abundance
(Figure 3-7).
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Figure 3-7. Hypothesis: miR-133a levels influence critical steps in ECM remodeling and
cellular phenotype throuqh the modulation of MT1-MMP protein abundance.
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CHAPTER 4: RESULTS AND DISCUSSION

Experimental Design:

Currently, there is limited research indicating

successful post transcriptional control of MT1-MMP with a single, specific
microRNA.

The studies described above have provided the mechanistic and

methodological structure for the work that follows.

Outcomes from this set of

investigations demonstrate post-transcriptional regulation of a key proteolytic
mediator of ECM remodeling, MT1-MMP, by miR-133a, and furthermore
determine the effects of modification on the phenotypic differences observed in
DeM myocardial fibroblasts. The stepwise approach: 1) defines the phenotypic
differences associated with determinants of ECM structure and function in DCM
myocardial fibroblasts; 2) establishes miR-133a as a post-transcriptional
regulator of MT1-MMP; and 3) demonstrates that in vitro modulation of miR-133a
can alter the defined phenotypic differences in OeM myocardial fibroblasts.
These studies contribute to a better understanding of the etiology of OeM
disease, and identify a modifiable endogenous regulatory target that may provide
the foundation for the development of novel therapeutics with the potential for
returning OeM phenotypic differences to normal.
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In order to identify potential regulatory microRNAs of MT1-MMP, a
bioinformatic approach was taken to examine the MT1-MMP transcript for
potential microRNA interaction sites. A TargetScan Human analysis, which is a
widely used predictor of biological targets of microRNAs, identified 5 potential
microRNA interactions, 3 of which were classified as 8mer targets meaning they
possess an exact match to positions 2-8 of the mature microRNA followed by an
adenosine molecule. This suggests a high likelihood for interaction, in that site
conservation is defined by conserved branch length, with an 8mer interaction
possessing the most stringent threshold conservation 56 . Upon further literature
review of the three leading 8mer microRNAs identified, miR-133a was found to
be enriched in cardiac and skeletal muscle and involved in cell specification,
differentiation,

and

development.

In

addition,

five

other bioinformatics

algorhythms (specifically: MicroCosm Targets Version 5; DIANA; PITA; RNA22 ;
and RNAhybrid) identified miR-133a as a strong candidate for potential
interaction with the same seed region of the MT1-MMP transcript (Figure 4-1).
- Seed Region -

MT1-MMP 3' UTR 5 '
(position 925-931 )

miR-133a

3'

... AGAGGGGGCAGGAGG G GACCAA ~
I III I IIIIII I
GUCGACCAACUUCC C CUGGUU U

...

Figure 4-1. miR-133a putative interaction site targeting the 3'UTR of MT1-MMP
transcript. The 8mer interaction site showing an exact match to positions 2-8 of the mature
miR-133a sequence followed by an adenosine molecule.

Furthermore, RNAhybrid is a tool for a putatively calculated determination of the
minimum free energy (mfe) hybridization of a long (3'UTR sequence) and a short
RNA (mature microRNA sequence). This tool is primarily intended for use as a
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means of microRNA target prediction by allowing the short sequence to hybridise
to the best fitting part of the longer sequence 30 . RNAhybrid provided a schematic
of miR-133a predicted binding within the MT1-MMP 3' UTR, and identified the
putative interaction as having a relatively low mfe of -35.2 kcal/mol, further
strengthening the possibility for interaction 30 (Figure 4-2) Therefore, miR-133a
was selected for further examination .
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Figure 4-2. miR-133a putative interaction site targeting the 3'UTR of MT1-MMP
transcript. The 8mer interaction site showing an exact match to positions 2-8 of the mature
miR-133a sequence followed by an adenosine molecule. The mfe of the predicted interaction
is -35.2 kcal/mol.

Current prediction algorithms calculate target efficacy based on interactions
between the mRNA with itself and the mRNA with a microRNA; however,
endogenously these interactions are occurring in a complex cellular environment
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in which mRNAs and microRNAs are likely bound by cellular RNA-binding
proteins, which is currently impossible to account for in silico.

Therefore,

investigation continued with quantification of miR-133a microRNA levels. Total
RNA was reverse transcribed with looped microRNA-specific RT primers
contained in the Taq-Man microRNA Human Assays (Applied Biosystems).
Single-stranded cDNA was synthesized from 10 ng total RNA in 15-uL reaction
volumes

with

TaqMan

microRNA

Reverse

Transcription

Biosystems), according to the manufacturer's protocol.

Kit

(Applied

The reaction was

incubated at 16°C for 30 min followed by 30 min at 42°C and inactivation at 85°C
for 5 min. Each cDNA was amplified with sequence-specific TaqMan microRNA
Assays from Applied Biosystems. peR reactions were performed on a Bio-Rad
CFX96 Real-Time System in 20 uL volumes in a 96-well plate at 95°C for 10 min,
followed by 45 cycles of 95°C for 15 sec and 60°C for 1 min. All samples were
tested in duplicate. The relative expression of each microRNA was calculated
and normalized to the small nucleolar RNA U47 (NR_002746.1) using the
comparative cycle threshold (CT) method (Livak and Schmittgen, 2001).
Relative expression intensity values were calculated as 2-~CT, in which ~CT are
CT values normalized to the referent control. Most interestingly, miR-133a levels
were found to be significantly reduced in LV myocardial fibroblasts isolated from
DeM patients when compared to normal (Figure 4-3). As previously mentioned,
aberrant microRNA expression is a recognized pathogenic means of disease,
therefore, results from this finding would suggest miR-133a may playa role in the
underlying pathogenesis.
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Figure 4-3. miR-133a microRNA Levels. miR-133a levels are reduced in LV myocardial
fibroblasts isolated from OeM patients (n=5) when compared to normal (n=4).

MicroRNAs impact nearly all physiological pathways, including apoptosis,
proliferation, pluripotency, differentiation, and cancer.

In order to begin the

process of unraveling the complex regulatory pathways governed by miR-133a,
tools for permanent over expression and inhibition will be employed. It should be
noted that while over expression or knockdown of a gene in a normal cell can
provide invaluable insight regarding its function, normalizing its levels during a
specific pathological condition is requisite for obtaining direct evidence regarding
its role in the underlying pathogenesis. Therefore, to accomplish the proposed
scientific objectives and investigate the role of miR-133a in OeM, a human
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myocardial fibroblast model of OeM, developed and validated by this research
group7t38t39, will be under investigation.

The defined phenotypic differences

observed in cultured OeM myocardial fibroblasts are consistent with clinical
specimens and have provided a basis for the advancement of a cell specific
strategy, targeting and regulating atypical MMP expression.

This model was

utilized in combination with a unique method to directly investigate miR-133a's
ability to modulate MT1-MMP protein abundance. To achieve modulation, one of
two bicistronic HIV-based Lentiviral Vectors allowed for delivery of a microRNA
precursor to the fibroblasts in culture.

Specific Aim 1: Demonstrate OeM fibroblasts have a unique phenotype
compared to normal fibroblasts.

Approach: The goal of this specific aim was to demonstrate key phenotypic

differences in cultured myocardial fibroblasts isolated from the left ventricle of
normal and DeM patients.

This set of studies established differential steady-

state MT1-MMP protein abundance and activity in DeM fibroblasts.

The

elevated levels of MT1-MMP likely contribute to changes in matrix structure and
function with DeM, therefore this aim established the relationship between the
phenotypic alterations in normal and OeM fibroblasts.

Specific Methods: Primary cultures of myocardial fibroblasts have been

established using a validated outgrowth technique. Full thickness LV myocardial
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samples were minced into several 2mm2 cubes under sterile conditions in a
laminar flow hood, then transferred to cell culture flasks and allowed to adhere.
Following a two week outgrowth period, these fibroblasts were sub-cultivated and
used to establish primary fibroblast cultures.

LV myocardial fibroblasts were

maintained in culture in an identical fashion as previously described (preliminary
studies). This has served as a test bed for the resolution of specific aim 1.

Response Variables:
abundance/activity,

The response variables were MT1-MMP protein

MT1-MMP

mRNA

levels,

and

MT1-MMP

ribosomal

distribution (methods and results in preliminary data section).

Data Analysis: Comparisons between groups were made using the Student's ttest (for pairwise comparisons) or two way analysis of variance (ANOVA) as
appropriate. Statistical tests were performed using STATA (Intercooled STATA
8, College Station, TX). Data are represented as mean +/- standard error of the
mean. A p value of <0.05 was considered to be statistically significant.

Specific Aim 2: Establish miR-133a as a post-transcriptional regulator
of MT1-MMP.

Approach: The goal of this specific aim was to confirm miR-133a as a direct
post-transcriptional regulator of MT1-MMP protein abundance in normal and
DCM myocardial fibroblasts. This set of studies demonstrated that Normal and
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DCM primary myocardial fibroblasts can be transduced by viral vectors to over
express miR-133a or anti-miR-133a.

Furthermore, following viral transduction,

the absence of an activated non-specific cellular stress response through
quantification of IFNJ31, OAS1, OAS2, MX1, ISGF3y and IFITM1 mRNA levels
was demonstrated in normal and DCM myocardial fibroblasts. Finally, this set of
studies has begun to establish the mechanism by which miR-133a regulates
MT1-MMP protein abundance by quantifying MT1-MMP transcript levels and
ribosomal distribution.

Specific Methods:

In Vitro microRNA Modulation. To investigate miR-133a's ability to modulate
MT1-MMP protein abundance, one of three bicistronic HIV-based Lentiviral
Vectors was employed to deliver a microRNA precursor to the fibroblasts or a
control-scrambled-sequence in the case of the vehicle control lentivector. This
control consisted of a non-targeting precursor Scrambled sequence control
hairpin in a pCDH-CMV-Scramble hairpin-EF1-copGFP lentivector (CD511 B-1;
System Biosciences; Mountain View, CA).

Over expression of miR-133a was

achieved with the use of the PMICRORNA 1-hsa-mir-133a-1 vector (CS970MR-1 ;
System Biosciences; Mountain View, CA). For knockdown of miR-133a, the antimiR-133a lentiviral construct (miRZip-133a anti-microRNA; CS970MZ-1; System
Biosciences; Mountain View, CA) vector was utilized for the production of singlestranded anti-microRNAs that competitively bind to endogenous miR-133a
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targets, inhibiting interaction with mRNA. In addition, both vectors co-express a
Green fluorescent protein, GFP, reporter under the control of independent
promoters. Each virus will express an individual microRNA precursor in its native
context while preserving hairpin structures to ensure biologically relevant
interactions with endogenous processing machinery and regulatory partners.

Transduction. Primary Human Cardiac Fibroblasts (2x105 Cells) were grown to

70%

confluence in sterile T-25 culture flasks (BO Falcon).

After 24hrs,

fibroblasts will be transduced with either a non-targeting precursor Scrambled
sequence control hairpin, an hsa-miR-133a lentiviral construct or an anti-miR133a lentiviral construct

with an MOl of 10 in a 1X concentration of a

transduction efficiency reagent, Transdux (L V850A-1; System Biosciences;
Mountain View, CA) in Fibroblast Basal Media with added supplement mix and
10% Fetal Bovine Serum.

Three days following transduction, the media

containing the introduced virus was aspirated from the culture flasks, cells were
rinsed once with PBS and media was replaced with fresh complete growth
media. Once the cells reached 100% confluence, they were trypsinized and split
into T-75 culture flasks at a seeding density of 5,000 per cm 2 , To demonstrate
feasibility of transduction, Figure 4-4 is representative of successful transduction
confirmation by visualization of the GFP reporter co-expressed by the vectors.
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Control

m1R-133a

Antl-mIR-133a

D.
LL
C)

Figure 4-4. Confirmation of Transduction: Lack of GFP reporter expression in the first
image confirms the absence of either vector, and positive GFP expression in the following two
images indicate successful transduction.

MT1-MMP mRNA levels. Five days following transduction, MT1-MMP mRNA
expression was determined by RT-qPCR (methods previously described:
Preliminary Studies).

Because microRNAs post-transcriptionally regulate

translation, no significant change was observed in both normal and OCM
myocardial fibroblasts.

As translational repression is an expected function of

miR-133a on MT1-MMP, effects were not mediated by a change in MT1-MMP
mRNA levels (Figure 4-5).
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Figure 4-5.
MT1-MMP mRNA Expression Following Transduction.
signifi ance was reached between groups.

Interferon Response Detection.

sequence-specific,

No statistical

RNA interference (RNAi) is a fundamental

mechanism

of

double-stranded

RNA

mediated

gene

regulation.

Although mammalian hosts have evolved defense mechanisms

against double-stranded RNA, typically present as consequence of viral infection,
these effects are not commonly present following microRNA delivery. Interferon
activates a signaling cascade, culminating in transcriptional activation of multiple
interferon stimulated genes.

Many of these ISGs function in stress response

pathways to mediate the cellular antiviral response; this will result in a global
reduction of translation. Although multiple studies have demonstrated efficient
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and specific silencing of gene expression with the use of chemically synthesized
double-stranded small interfering RNAs (siRNA) or vector based short hairpin
RNAs, increasing evidence reporting the potent induction of interferons (IFNs)
and pro-inflammatory cytokines both in vitro and in vivo, therefore limiting the
efficacy of their use58 .

Alternatively, microRNAs possess a preserved hairpin

structure known to ensure a biologically relevant interaction with endogenous
processing machinery and regulatory partners, thereby limiting the possibilities of
off-target interactions and activation of IFNs and inflammatory cytokines 56 .
Therefore, to confirm the specificity of the RNAi knockdown phenotype or
response, six genes associated with induction of an interferon response were
examined by RT-qPCR following transduction by the CD511 virus, a control
lentivector containing a scrambled sequence, the miR-133a lentivector or the antmiR-133a lentivector (methods previously discussed).

The adherent, human

firosarcoma cell line, HT1080, was utilized in the production of a positive
interferon response control. The HT1080 cells were treated with 1,000 IU/mL
Interferon Beta (BioAbChem, specific activity: 2.7x108 IU/mg) for 24 hours to elicit
an interferon response 55 .

Interferon-~1 (IFN~1) is known to be produced by

fibroblasts and possesses antiviral activity which is mainly involved in the innate
immune response. The genes encoding 2'5'-0Iigoadenlylate synthetases (OAS1
and OAS2) are important interferon-induced genes for the inhibition of cellular
protein synthesis following viral infection.

The product of the MX1 gene is a

member of the interferon induced myxovirus resistance protein family, and
participates in the innate host defense against RNA viruses, and was not
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detected in either control IFN stimulated cells or experimental. As a virus was
not utilized to stimulate the IFN response in control cells the absence of the MX1
signal suggested that the interferon response was not previously stimulated by
viral infection.

ISGF3y is part of a cellular interferon receptor involved in

interferon induced transcription regulation and stimulation. IFITM1, a member of
the interferon inducible transmembrane proteins, mediates the anti-proliferation
activity of interferon.

As induction of an interferon response is defined as a

robust increase in all of the following mRNAs55 , the observation that no
significant induction of IFNJ31, OAS1, OAS2, MX1, ISGF3y and IFITM1 mRNA
levels following microRNA transduction, suggested that the gene silencing
induced by miR-133a was not associated with induction of a nonspecific
interferon response (Figure 4-7).
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Figure 4-7. Interferon Response Detection. As induction of an interferon response is
defined as a robust increase in all of the following mRNAs, the observation that no significant
induction of IFNf31, OAS1, OAS2, MX1, ISGF3y and IFITM1 mRNA levels following microRNA
transduction, suggested that the gene silencing induced by miR-133a was not associated with
induction of a nonspecific interferon response. Groups were pooled (normal n=4, OeM n=5)
and data shown as a ratio to non-transduced referent control.

MT1-MMP 3'UTR Target Confirmation. To confirm miR-133a directly targets
MT1-MMP's 3'UTR, a commercially available 3'UTR reporter vector (SwitchGear
Genomics) was constructed by cloning the 3'UTR of the human MT1-MMP gene
downstream of a luciferase open reading frame. This method essentially places
luciferase expression under the direct control of MT1-MMP's 3'UTR. This allows
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for the quantifiable determination of active translation specifically occurring.
Therefore co-transfection of the reporter vector with a microRNA mimic that
targets the inserted 3'UTR, will result in repression of luciferace translation. The
adherent, human firosarcoma cell line, HT1080, was utilized in the target site
confirmation within MT1-MMP's 3'UTR. HT1080 cells were co-transfected in a
96-well plate with the LightSwitch MT1-MMP 3' UTR reporter GoClone plasmid or
the empty 3'UTR vector, GAPDH 3'UTR or R_02 (random sequence) 3'UTR as
controls, in combination with a miR-133a microRNA mimic or non-mammalian
mRNA targeting microRNA mimic as a control.

The empty 3'UTR vector

contained only the luciferase gene (RenSP) and its constitutive promoter. This
construct served as a positive control for the transfection because of its
promoter. The GAPDH 3'UTR vector is a housekeeping control construct, and
contained the 3'UTR from the housekeeping control gene GAPDH cloned
downstream of the RenSP luciferase reporter.

The random control sequence

3'UTR vector construct contained non-conserved, non-genic, and non-repetitive
human genomic fragments inserted downstream of the RenSP luciferase
reporter. Reporter assays were performed at 24 hours following transfection with
DharmaFECT -Duo transfection reagent by the LightSwitch Luciferase Assay
system (SwitchGear Genomics) (Figure 4-8). Luminescence will be quantitated
by luminometer. All transfection experiments were performed four times in
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Figure 4-8 . Overview of methods involved in confirmation of microRNA target recognition

triplicate. The results of this study were a decrease in luminescence observed in
cells co-transfected with the MT1-MMP 3' UTR reporter GoClone plasmid and
the miR-133a microRNA mimic, and no significant change in controls,
demonstrating targeted interaction of miR-133a to the MT1-MMP 3'UTR (Figure

4-9).
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Figure 4-9. Confirmation that miR-133a directly targets MT1 -MMP's 3'UTR in vitro.

Data Analysis: Comparisons between groups were made using the Student's ttest (for pairwise comparisons) or two way analysis of variance (ANOVA) as
appropriate. Statistical tests were performed using STATA (Intercooled STATA
8, College Station, TX). Data are represented as mean +/- standard error of the
mean. A P value of <0.05 was considered to be statistically significant.
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Specific Aim 3: Determine the effect of miR-133a modulation on
phenotypic differences between normal and OeM fibroblasts.

Approach: Over expression and knockdown of miR-133a in a normal cell may

provide invaluable insight regarding its function on MT1-MMP and the defined
phenotypic differences between normal and OCM; however, normalizing
phenotype via modulation of miR-133a during pathological OeM is requisite for
obtaining direct evidence regarding its role in the underlying pathogenesis. The
goal of this specific aim is to determine the consequence of miR-133a modulation
on the phenotypic differences defined in specific aim 1.

Specific Methods:

MT1-MMP protein abundance. Five days following transduction, the relative
abundance of MT1-MMP protein was determined by immunoblotting (methods
previously described: Preliminary Studies). It was found that when compared to
respective referent controls, a reduction of MT1-MMP protein abundance was
observed with miR-133a over expression as well as a significant increase in
MT1-MMP protein abundance with miR-133a knockdown, in both normal (Figure

4-10) and OCM (Figure 4-11) myocardial fibroblasts.

Sample Sizes: Normal, n=4; DCM, n=5. Completion of this specific aim required

four identical cultures of each cell type treated with the following: Transduction
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efficiency reagent alone, control-scrambled-sequence lentivector, miR-133a
precursor lentivector, and anti-miR-133a precursor lentivector.

Results: It was observed that over expression of the miR-133a precursor
resulted in decreased MT1-MMP protein abundance, while knockdown of miR133a by expression of the anti-microRNA-133a result in a dramatic increase of
MT1-MMP protein abundance in Normal (Figure 4-10) and DeM (Figure 4-11)
myocardial fibroblasts.

Furthermore, Figure 4-12 demonstrates that by

increasing miR-133a levels in DeM myocardial fibroblasts, aberrant MT1-MMP
protein abundance may be returned to within normal range.
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Figure 4-10. Normal MT1-MMP Protein Abundance. This graph is reflective of percent
change in MT1-MMP protein abundance when compared to respective referent controls
following transduction, and shows a reduction of MT1-MMP protein abundance with miR -133a
over expression , and a significant increase of MT1-MMP protein abundance with miR-133a
knockdown. (Normalized to Beta Actin)
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Figure 4-12. miR-133a's Ability to Reduce Aberrant MT1-MMP Protein Abundance in
OeM Myocardial Fibroblasts to within Normal Range.

Data Analysis: Comparisons between groups were made using the Student's ttest (for pairwise comparisons) or two way analysis of variance (ANOVA) as
appropriate. Statistical tests were performed using STATA (Intercooled STATA
8, College Station, TX). Data are represented as mean +/- standard error of the
mean. A P value of <0.05 was considered to be statistically significant.
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CHAPTER 5: FUTURE DIRECTIONS

The following section will provide insight for future directions of this study as
well as preliminary feasibility data to demonstrate that the proposed directions
are achievable.

Determination of Cell Functionality. A cause and effect relationship has been
established between MMP activity and the LV remodeling process associated
with DCM. Therefore, we will seek to determine a quantifiable assessment of the
differential biological phenotype of DCM myocardial fibroblasts in respect to
several determinants of ECM structure: cell proliferation, adhesion, and
migration.

Proliferation. Cells will be seeded at 1,000 cells per well of a 96 well clear
bottom plate (Costar Flat bottom Cell bind Surface [Poly-D-Lysine] Cat# 3300,
Corning, NY), and allowed to adhere overnight. The following day growth media
will be aspirated and replaced with fresh complete media. CyQuant Direct Cell
Proliferation Assay (Cat#C35011, Molecular probes) kit will then be used to
determine cell number. The basis of the CyQUANT kit is the use of a green
fluorescent dye, which exhibits strong fluorescence enhancement when bound to
cellular nucleic acids. This kit will be allowed to equilibrate to room temperature
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and the following will be mixed: PBS (97.50/0), Cyquant Direct nucleic acid stain
(0.004%), and direct background suppressor (0.02%).

12 hours following the

addition of fresh complete phenol-free fibroblast growth media, an equal volume
of 2X Detection reagent will be added to the cells in the culture media (assay is
compatible in media with or without serum). Cells will then be incubated for 1
hour at 37C with 5% CO 2 • Following one hour incubation time, fluorescence will
be read from the bottom of the well at 480/535 Ex/Em. This will then be repeated
at 24, 36, 48, 60, 72, 84, and 96 hours. For each cell line, a standard curve will
be generated by preparation of a serial dilution of cell numbers ranging from 500
to 5,000. These cells will be allowed to adhere overnight, and then the cells will
be assayed directly by CyQUANT.

Fluorescence will then be read from the

bottom of the well at 480/535 Ex/Em. Relative fluorescence correlates linearly
with cell number. As a proof of concept, preliminary results from this assay have
identified that proliferation rate is significantly higher in DCM myocardial
fibroblasts when compared to normal (Figure 5-1).
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Figure 5-1. Cell Proliferation: OeM (n=5) myocardial fibroblast proliferation rate is
significantly higher than normal (n=4) cells.

Adhesion. Myocardial fibroblasts, 2,000 cells per well, will be seeded in 100 uL
of complete growth media per well of a 96 well clear bottom plate (Costar Flat
bottom Cell bind Surface [Poly-D-Lysine] Cat #3300, Corning, NY).

Cells are

then allowed to adhere by returning the plate to the incubator for 1 hour in
standard tissue culture conditions. The plate will then be washed five times with
room temperature PBS (with Ca2+/Mg2+) using a BioPlex Pro Plate Washing
Station set to "Drip Fill" to achieve consistency in washes across plates. Each
well will then be carefully aspirated so as to not disturb the cells, and 100 uL of
complete, phenol-free fibroblast growth media will be added to the cells. Cells will
then be fluorescently labeled with CyQUANT, and relative fluorescence will be
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quantitated by microplate reader.

Cell number will then be obtained by

comparing relative fluorescence values to a standard curve made with a known
dilution

of

cells

(methods

previously

described:

Proliferation).

As

a

demonstration of feasibility, results from this assay have identified that cellular
adhesion to a Poly-O-Lysine coated surface is significantly reduced in OCM
myocardial fibroblasts (Figure 17). Combined, the results from both adhesion
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Figure 17. Cell Adhesion: Adhesion to a Poly-D-Lysine coated surface is reduced in DeM
(n=5) myocardial fibroblasts when compared to normal (n=4).

and proliferation assays suggest that a significant and stable transformation of
fibroblast phenotype, and thereby function may occur within the myocardial ECM
with the development of OCM.
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Migration.

Cell migration is a fundamental cell behavior critical for many

physiological and pathological events, such as the inflammatory response and
heart failure.

To compare migration properties between normal and DCM

myocardial fibroblasts, The Oris Cell Migration Assay will be performed. This is a
multistep process that starts with the application of a mask to the bottom of the
wells of a 96-well, Poly-D-Lysine coated, microplate. Next, a polymeric insert is
fitted to the inside of the wells of the microplate. This insert prevents cells from
seeding the inner analytic zone of the well when cells are added to the wells of
the microplate. Myocardial fibroblasts (2x10 3 cells per well) will be seeded in 100
uL of complete fibroblast growth media. After cell attachment has occurred, the
inserts will be removed. Wells will then be gently washed with fibroblast growth
media, and cells will then receive 100 uL of fresh complete fibroblast growth
media. Plates will then be returned to the incubator, allowing the fibroblasts to
freely migrate into the central analytic zone of the wells. Fibroblasts that have
not migrated into the analytic zone are blocked from view by the mask initially
applied to the plate bottom. Based on the results from the proliferation assay,
the approximate doubling time of the myocardial fibroblasts in culture, is 24 to 48
hours.

Therefore, to avoid the chance of proliferation occurring during the

migration period, the migrated fibroblasts will be quantified by CyQUANT assay,
and cell number will be determined by standard curve (methods described in
previous section: Proliferation) following 6 and 12 hour incubation times. Each
assay will be performed in triplicate and the results will be averaged.

The

anticipated outcome of this study is an increase in density of fibroblasts on the
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inner analytic zone in OeM when compared to normal, suggesting OeM
myocardial fibroblasts have an increased migration rate.

MT1-MMP Translational

Efficiency.

Following transduction,

MT1-MMP

translational efficiency was determined by ribosomal distribution (methods
previously described: Preliminary Studies). It was observed in a subset sample
size of 1 normal, 1 OeM and 1 OeM cell line transduced with the miR-133a
lentivector, that following over expression of miR-133a, specifically MT1-MMP
predominantly shifted from polyribosomal to monoribosomal fractions in OeM
myocardial fibroblasts (Figure 4-6).
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Figure 4-6. MT1-MMP and GAPDH Ribosomal mRNA Distribution. (n=1)
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TNFa, IL-1 and IL-6 Stimulation and Gene Expression Analysis.

The

importance of pro-inflammatory mediators in the development of heart failure has
recently become apparent.

Following myocardial infarction (MI), the acute

inflammatory phase serves initially to drive tissue repair and adaptation to
injury45; however, prolonged expression of pro-inflammatory cytokines is
detrimental and can lead to progressive heart failure 51 . The pro-inflammatory
cytokines: tumor necrosis factor a (TNFa), interleukin-1 (IL-1), and interleukin-6
(IL-6), are key in this myocardial inflammatory response 4 .

Cardiomyocytes

respond to many pro-inflammatory cytokines by undergoing apoptosis and/or
hypertrophy, while myocardial fibroblasts undergo a phenotype change and
endure increased proliferation and collagen turnover, contributing to the adverse
post-MI remodeling that can ultimately lead to heart failure 51 .

Therefore, to

demonstrate a differential response in mRNA expression patterns between
normal (n=4) and OeM (n=5), an established concentration of purified
recombinant pro-inflammatory cytokines TNFa (10ng/mL), IL-1 (100 pg/mL) and
IL-6 (100 pg/mL), will be delivered to the cells in reduced serum fibroblast growth
media for a 24 hour time period. Following stimulation, the cells will be collected
as previously described (Preliminary Studies). Total RNA will then be isolated
and pooled into either normal or DCM. Assessment and quantification will be
performed by methods previously described (Preliminary Studies).

One

microgram of high-quality RNA from each pool will be reverse-transcribed to
generate cDNA using an RT2 First Strand Kit (Cat#C-03, SABiosciences,
Frederick, MD), and the cDNA will then be immediately assayed for gene
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expression by quantitative PCR. To easily assess the expression of numerous
genes from the RNA pools, a custom RT2 Profiler PCR Array (Custom Services;
SABiosciences) has been designed to test 42 different genes, including 4
housekeeping control genes, in a 96-well plate format. The generated cDNA will
be diluted into RT2 qPCR Master Mix (Cat#PA-011, containing Hot-Start Taq
polymerase and a SYBR Green/Fluorescein mix specific for Bio-Rad qPCR
systems; SABiosciences), according to the manufacturer's instructions, and then
applied to a 96-well PCR Array plate. PCR will be performed using a MyiQ
Single-Color Real-Time PCR Detection System (Bio-Rad) with the following
cycling parameters: initial denaturation for 10 minutes at 95°C was followed by
40 cycles of 15 seconds at 95°C, 40 seconds at 55°C, and 30 seconds at 72°C.
A melt curve will be established immediately following the conclusion of the
cycling program to allow for confirmation of a single PCR product for each genespecific primer set (1 minute at 95°C, 2 minutes at 65°C, followed by 60 cycles of
15 seconds at 65°C with an increase of 0.5°C per cycle). Negative controls will
be included on each plate to verify the absence of genomic DNA contamination
(no reverse transcription control) and the absence of overall DNA contamination
in the PCR system and working environment (no template control). Ct values will
then be determined and fold change in steady-state gene expression between
normal and DCM myocardial fibroblast will be calculated using the previously
described method. Fold expression values greater than 2.0 or less than 0.5 will
be considered a significant change in gene expression. In addition, any gene
that displays a significant difference in mean
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may result in increased adhesion, while expression of the anti-miR-133a may
result in decreased adhesion, in both normal and DeM myocardial fibroblasts.

Migration. Five days following transduction, migration rate will be determined by
methods previously described: Specific Aim 1. It is anticipated that following over
expression of miR-133a may result in a reduced migration rate, while expression
of the anti-miR-133a may result in increased migration in both normal and DeM
myocardial fibroblasts.

TNFa, IL-1 and IL-6 Stimulation and Gene Expression Analysis. Five days
following transduction, the myocardial fibroblasts will be stimulated with proinflammatory cytokines, and effects on expression of 42 functionally related
mRNAs will be quantitated by methods previously described (ABOVE).

It is

anticipated that following over expression of miR-133a in DeM myocardial
fibroblasts may return expression patterns to within normal ranges, while
expression of the anti-miR-133a in normal myocardial fibroblasts may result in an
expression pattern consistent with that observed in DeM.

Response Variables: The response variables will be: cell adhesion, proliferation
"and migration; and gene expression analysis following TNFa, IL-1 and IL-6
stimulation.
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CHAPTER 6: SUMMARY

Outcomes from this set of investigations demonstrate translational regulation
of a key proteolytic mediator of ECM remodeling, MT1-MMP, by miR-133a, and
furthermore determine the effects of modification on the phenotypic differences
observed in OCM myocardial fibroblasts. The stepwise approach: 1) defined the
phenotypic differences associated with determinants of ECM structure and
function in OCM myocardial fibroblasts; 2) established miR-133a as a posttranscriptional regulator of MT1-MMP; and 3) demonstrated that in vitro
modulation of miR-133a can alter the defined phenotypic differences in OCM
myocardial fibroblasts. These studies contribute to a better understanding of the
etiology of DCM disease, and identify a modifiable endogenous regulatory target
that may provide the foundation for the development of novel therapeutics with
the potential for returning DCM phenotypic differences to normal.
This study has demonstrated translational regulation of MT1-MMP protein
abundance by direct modulation of miR-133a in normal and OCM myocardial
fibroblasts, without induction of an interleron response.

Identification of the

cellular and molecular pathways responsible for the specific alterations
correlating with disease state holds diagnostic and therapeutic relevance for one
of the most urgent public health problems in the United States.
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